Latest On Galapagos NV (GLPG):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-06 09:51 EST | News | Galapagos Stands Strong On Jyseleca Positive Clinical Data | N/A |  |
| 2023-05-05 21:26 EST | News | Galapagos NV (GLPG) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-04 19:34 EST | News | Galapagos GAAP EPS of €0.40, revenue of €178.9M | N/A | |
| 2023-05-03 18:15 EST | News | Galapagos Q1 2023 Earnings Preview | N/A | |
| 2023-05-03 05:16 EST | News | Galapagos announces departure of COO and CFO Bart Filius | N/A | |
| 2023-03-30 21:01 EST | News | Galapagos to transfer drug discovery and research activities in France to NovAliX | N/A | |
| 2023-02-24 11:36 EST | News | Galapagos NV (GLPG) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-23 22:33 EST | News | Galapagos reports FY 2022 results, sees further reduction of cash burn in FY 2023 | N/A | |
| 2023-02-11 10:09 EST | News | Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating | N/A | |
| 2023-02-09 18:47 EST | News | Galapagos stock dips as Jyseleca fails phase 3 trial as induction therapy in Crohn's disease, cancels plan for EU filing | N/A | |
| 2023-02-08 02:22 EST | News | Galapagos: Deeply Into Negative EV Territory, Exciting BD Optionality, Buy | N/A | |
| 2022-12-31 07:11 EST | News | Galapagos: Slow Transformation, But Led By An Expert | N/A | |
| 2022-11-07 11:28 EST | News | Galapagos downgraded to market perform at Raymond James on unclear path forward | N/A | |
| 2022-11-03 19:29 EST | News | Galapagos GAAP EPS of -€0.16, revenue of €410.2M | N/A | |
| 2022-11-03 02:25 EST | News | Galapagos Q3 2022 Earnings Preview | N/A | |
| 2022-10-10 20:03 EST | News | Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product | N/A | |
| 2022-10-03 19:25 EST | News | EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects | N/A | |
| 2022-09-09 14:41 EST | News | Galapagos cut at Morgan Stanley on positive but slow transformation | N/A | |
| 2022-08-06 18:23 EST | News | Galapagos NV (GLPG) CEO Paul Stoffels on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-04 20:20 EST | News | Galapagos GAAP EPS of -€0.49, revenue of €274M | N/A | |
| 2022-07-25 21:27 EST | News | Galapagos stock dips after Jefferies slashes rating citing challenges ahead | N/A | |
| 2022-06-21 19:06 EST | News | Galapagos to enter cell therapy space with acquisition of CellPoint and AboundBio | N/A | |
| 2022-05-30 23:31 EST | News | Morgan Stanley updates biotechs with negative enterprise values & 2022 catalysts | N/A | |
| 2022-05-25 07:04 EST | News | Galapagos to license drug targets for inflammatory bowel disease from Scipher Medicine | N/A | |
| 2022-05-20 09:10 EST | News | Galapagos: Can The Company Turn Around? | N/A | |
| 2022-05-06 13:39 EST | News | Galapagos GAAP EPS of -€0.20, revenue of €136.3M | N/A | |
| 2022-05-06 13:39 EST | News | Galapagos NV (GLPG) CEO Paul Stoffels on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-06 13:38 EST | News | Galapagos NV 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-05-05 15:51 EST | News | Galapagos Q1 2022 Earnings Preview | N/A | |
| 2022-03-28 07:24 EST | News | Gilead, Galapagos' Jyseleca gets approval in Japan for expanded use in ulcerative colitis | N/A | |
| 2022-02-25 18:23 EST | News | Galapagos NV (GLPG) CEO Onno van de Stolpe on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-25 01:06 EST | News | Galapagos GAAP EPS of -€1.58, revenue of €484.85M | N/A | |
| 2022-02-24 05:28 EST | News | Galapagos Q4 2021 Earnings Preview | N/A | |
| 2022-02-22 14:27 EST | News | Galapagos: A History Of Disruptive Failures | N/A | |
| 2022-01-28 00:18 EST | News | Galapagos at a six-month high after naming former J&J science chief as CEO | N/A | |
| 2022-01-27 07:39 EST | News | Galapagos creates 1M subscription rights; stock rises 9% | N/A | |
| 2022-01-26 14:26 EST | News | Einhorn's Greenlight discloses positions in Global Payments, Capri, Galapagos, ODP Corp. | N/A | |
| 2022-01-19 05:53 EST | News | Galapagos' Jyseleca wins UK marketing authorization for ulcerative colitis | N/A | |
| 2022-01-09 00:57 EST | News | Biogen, Galapagos and Ultragenyx among key biotech calls at Morgan Stanley for 2022 | N/A | |
| 2021-12-04 00:46 EST | News | Galapagos announces increase in share capital with subscription right exercises | N/A | |
| 2021-12-02 09:17 EST | News | Galapagos: The Investment Thesis Is More Appealing Than Ever | N/A | |
| 2021-11-15 16:53 EST | News | Galapagos wins EU approval for Jyseleca for ulcerative colitis | N/A | |
| 2021-11-08 23:33 EST | News | Galapagos rises as analysts highlight a major catalyst ahead | N/A | |
| 2021-11-05 17:29 EST | News | Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-04 20:49 EST | News | Galapagos reports Q3 results | N/A | |
| 2021-11-03 23:37 EST | News | Galapagos Q3 2021 Earnings Preview | N/A | |
| 2021-10-04 18:03 EST | News | Galapagos posts results from post-hoc analyses of filgotinib in ulcerative colitis | N/A | |
| 2021-09-22 14:07 EST | News | Galapagos' filgotinib wins positive CHMP opinion for treatment of ulcerative colitis | N/A | |
| 2021-08-19 18:51 EST | News | Galapagos lowered to equal weight at Barclays; doubts acquisition driven upside | N/A | |
| 2021-08-08 04:48 EST | News | Galapagos NV (GLPG) CEO Onno van de Stolpe on Q2 2021 Results - Earnings Call Transcript | N/A | |
About Galapagos NV (GLPG):
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
General
- Name Galapagos NV
- Symbol GLPG
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Fiscal Year EndDecember
- IPO Date2005-05-06
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.glpg.com
View More
Valuation
- Trailing PE 60.65
- Price/Sales (Trailing 12 Mt.) 9.78
- Price/Book (Most Recent Quarter) 1.69
- Enterprise Value Revenue 1.18
- Enterprise Value EBITDA 3.11
View More
Financials
- Most Recent Quarter 2020-09-30
- Current Year EPS Estimate -$4.89
- Next Year EPS Estimate -$4.50
- Next Quarter EPS Estimate -$0.28
- Profit Margin -58%
- Return on Assets -2%
- Return on Equity -11%
- Earnings Per Share -$1.69
- Revenue Per Share $0
- Gross Profit 6.6 million
- Quarterly Earnings Growth -77.6%
View More
Highlights
- Market Capitalization 5.28 billion
- Analyst Target Price $93.67
- Book Value Per Share $25.49
View More
Share Statistics
- Shares Outstanding 65.41 million
- Shares Float 43.14 million
- % Held by Insiders <1%
- % Held by Institutions 11.77%
- Shares Short 936943
- Shares Short Prior Month 966729
- Short Ratio 2.3
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 0.28
- 52 Week High $233.14
- 52 Week Low $79.59
- 50 Day Moving Average 90.41
- 200 Day Moving Average 114.01
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Galapagos NV (GLPG) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Galapagos NV (GLPG) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-18 | -$1.06 | -$1.53 | 30.28% | |
| 2020-09-30 | 2020-11-05 | $131.82 million | -$1.49 | -$0.99 | -51.08% |
| 2020-06-30 | 2020-08-06 | $N/A | -$2.10 | -$0.85 | -147.49% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.85 | -$0.86 | 2.01% |
| 2019-12-31 | 2020-02-20 | $160.81 million | -$2.34 | -$0.79 | -193.91% |
| 2019-09-30 | 2019-10-24 | $701.86 million | $7.05 | $3.29 | 114.55% |
| 2019-06-30 | 2019-07-25 | $76.28 million | -$0.97 | -$1.25 | 22.41% |
| 2019-03-31 | 2019-04-25 | $45.88 million | -$0.99 | -$1.02 | 2.59% |
| 2018-12-31 | 2019-02-21 | $129.35 million | $0.31 | -$0.90 | 134.1% |
| 2018-09-30 | 2018-10-24 | $119.48 million | $0.32 | -$1.10 | 129.08% |
| 2018-06-30 | 2018-08-02 | $66.38 million | -$0.49 | -$1.00 | 51.42% |
| 2018-03-31 | 2018-04-25 | $55.24 million | -$0.89 | -$1.11 | 19.74% |
| 2017-12-31 | 2018-02-22 | $61.81 million | -$0.73 | -$0.91 | 20.04% |
| 2017-09-30 | 2017-10-26 | $42.3 million | -$0.84 | -$0.93 | 10.37% |
| 2017-06-30 | 2017-07-27 | $40.69 million | -$0.86 | -$0.67 | -29.5% |
| 2017-03-31 | 2017-04-27 | $42.65 million | -$0.32 | -$0.59 | 46.03% |
| 2016-12-31 | 2017-02-23 | $86.89 million | $1.05 | $0.10 | 897.14% |
| 2016-09-30 | 2016-10-27 | $19.3 million | -$0.57 | -$0.66 | 14.05% |
| 2016-06-30 | 2016-07-28 | $36.92 million | -$0.11 | -$0.21 | 46.22% |
| 2016-03-31 | 2016-04-28 | $16.88 million | $0.89 | $1.30 | -31.2% |
| 2015-12-31 | 2016-03-03 | $13.08 million | -$1.69 | -$0.84 | -101.49% |
| 2015-09-30 | 2015-11-13 | $11.52 million | -$0.72 | $4.06 | -117.73% |
| 2015-06-30 | 2015-08-06 | $19.68 million | -$0.59 | -$0.35 | -68.57% |
Galapagos NV (GLPG) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Galapagos NV (GLPG) Chart:
Galapagos NV (GLPG) News:
Below you will find a list of latest news for Galapagos NV (GLPG) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Galapagos NV (GLPG) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-08-15 | 15 | 0 | CALL | 0 | 0 | 342.11 | TRUE | 0 | 0 |
| 2025-08-15 | 17.5 | 0 | CALL | 0 | 0 | 105.66 | TRUE | 0 | 0 |
| 2025-08-15 | 20 | 0 | CALL | 0 | 0 | 238.8 | TRUE | 0 | 0 |
| 2025-08-15 | 22.5 | 0 | CALL | 0 | 0 | 192.32 | TRUE | 0 | 0 |
| 2025-08-15 | 25 | 0 | CALL | 0 | 0 | 60.05 | TRUE | 0 | 0 |
| 2025-08-15 | 27.5 | 0 | CALL | 0 | 0 | 104.61 | TRUE | 0 | 0 |
| 2025-08-15 | 30 | 1.5 | CALL | 0 | 46 | 54.88 | TRUE | 0 | 0 |
| 2025-08-15 | 32.5 | 0.9 | CALL | 0 | 10002 | 46.46 | FALSE | 0 | 0 |
| 2025-08-15 | 35 | 0 | CALL | 0 | 0 | 107.6 | FALSE | 0 | 0 |
| 2025-08-15 | 37.5 | 0 | CALL | 0 | 0 | 136.05 | FALSE | 0 | 0 |
| 2025-08-15 | 40 | 0 | CALL | 0 | 0 | 154 | FALSE | 0 | 0 |
| 2025-08-15 | 42.5 | 0 | CALL | 0 | 0 | 169.86 | FALSE | 0 | 0 |
| 2025-08-15 | 15 | 0 | PUT | 0 | 0 | 354.12 | FALSE | 0 | 0 |
| 2025-08-15 | 17.5 | 0 | PUT | 0 | 0 | 297.24 | FALSE | 0 | 0 |
| 2025-08-15 | 20 | 0 | PUT | 0 | 0 | 248.68 | FALSE | 0 | 0 |
| 2025-08-15 | 22.5 | 0 | PUT | 0 | 0 | 205.76 | FALSE | 0 | 0 |
| 2025-08-15 | 25 | 0 | PUT | 0 | 0 | 166.62 | FALSE | 0 | 0 |
| 2025-08-15 | 27.5 | 0.05 | PUT | 0 | 2016 | 59.23 | FALSE | 0 | 0 |
| 2025-08-15 | 30 | 3.58 | PUT | 0 | 1000 | 91.51 | FALSE | 0 | 0 |
| 2025-08-15 | 32.5 | 0 | PUT | 0 | 0 | 50.51 | TRUE | 0 | 0 |
| 2025-08-15 | 35 | 0 | PUT | 0 | 0 | 88.66 | TRUE | 0 | 0 |
| 2025-08-15 | 37.5 | 0 | PUT | 0 | 0 | 57.82 | TRUE | 0 | 0 |
| 2025-08-15 | 40 | 0 | PUT | 0 | 0 | 74.31 | TRUE | 0 | 0 |
| 2025-08-15 | 42.5 | 0 | PUT | 0 | 0 | 95.27 | TRUE | 0 | 0 |
| 2025-09-19 | 17.5 | 0 | CALL | 0 | 0 | 64.55 | TRUE | 0 | 0 |
| 2025-09-19 | 20 | 0 | CALL | 0 | 0 | 57.07 | TRUE | 0 | 0 |
| 2025-09-19 | 22.5 | 0 | CALL | 0 | 0 | 66.55 | TRUE | 0 | 0 |
| 2025-09-19 | 25 | 0 | CALL | 0 | 0 | 36.86 | TRUE | 0 | 0 |
| 2025-09-19 | 27.5 | 0 | CALL | 0 | 0 | 34.84 | TRUE | 0 | 0 |
| 2025-09-19 | 30 | 0 | CALL | 0 | 0 | 35.72 | TRUE | 0 | 0 |
| 2025-09-19 | 32.5 | 0 | CALL | 0 | 0 | 59.2 | FALSE | 0 | 0 |
| 2025-09-19 | 35 | 0 | CALL | 0 | 0 | 75.12 | FALSE | 0 | 0 |
| 2025-09-19 | 37.5 | 0 | CALL | 0 | 0 | 88.97 | FALSE | 0 | 0 |
| 2025-09-19 | 40 | 0 | CALL | 0 | 0 | 100.88 | FALSE | 0 | 0 |
| 2025-09-19 | 42.5 | 0 | CALL | 0 | 0 | 111.38 | FALSE | 0 | 0 |
| 2025-09-19 | 45 | 0 | CALL | 0 | 0 | 120.81 | FALSE | 0 | 0 |
| 2025-09-19 | 17.5 | 0 | PUT | 0 | 0 | 197.07 | FALSE | 0 | 0 |
| 2025-09-19 | 20 | 0 | PUT | 0 | 0 | 165.01 | FALSE | 0 | 0 |
| 2025-09-19 | 22.5 | 0 | PUT | 0 | 0 | 136.69 | FALSE | 0 | 0 |
| 2025-09-19 | 25 | 0 | PUT | 0 | 0 | 110.89 | FALSE | 0 | 0 |
| 2025-09-19 | 27.5 | 0 | PUT | 0 | 0 | 86.56 | FALSE | 0 | 0 |
| 2025-09-19 | 30 | 0 | PUT | 0 | 0 | 63.5 | FALSE | 0 | 0 |
| 2025-09-19 | 32.5 | 0 | PUT | 0 | 0 | 51.99 | TRUE | 0 | 0 |
| 2025-09-19 | 35 | 0 | PUT | 0 | 0 | 35.03 | TRUE | 0 | 0 |
| 2025-09-19 | 37.5 | 0 | PUT | 0 | 0 | 31.99 | TRUE | 0 | 0 |
| 2025-09-19 | 40 | 0 | PUT | 0 | 0 | 53.94 | TRUE | 0 | 0 |
| 2025-09-19 | 42.5 | 0 | PUT | 0 | 0 | 62.61 | TRUE | 0 | 0 |
| 2025-09-19 | 45 | 0 | PUT | 0 | 0 | 61.43 | TRUE | 0 | 0 |
| 2025-10-17 | 12.5 | 0 | CALL | 0 | 0 | 222.15 | TRUE | 0 | 0 |
| 2025-10-17 | 15 | 0 | CALL | 0 | 0 | 184.79 | TRUE | 0 | 0 |
| 2025-10-17 | 17.5 | 0 | CALL | 0 | 0 | 151.05 | TRUE | 0 | 0 |
| 2025-10-17 | 20 | 0 | CALL | 0 | 0 | 128.1 | TRUE | 0 | 0 |
| 2025-10-17 | 22.5 | 0 | CALL | 0 | 0 | 109.92 | TRUE | 0 | 0 |
| 2025-10-17 | 25 | 4.8 | CALL | 0 | 55 | 38.36 | TRUE | 0 | 0 |
| 2025-10-17 | 27.5 | 0 | CALL | 0 | 2 | 23.68 | TRUE | 0 | 0 |
| 2025-10-17 | 30 | 2.75 | CALL | 0 | 324 | 28.58 | TRUE | 0 | 0 |
| 2025-10-17 | 32.5 | 1.75 | CALL | 0 | 58 | 47.61 | FALSE | 0 | 0 |
| 2025-10-17 | 35 | 0.5 | CALL | 0 | 69 | 61.74 | FALSE | 0 | 0 |
| 2025-10-17 | 37.5 | 0.9 | CALL | 0 | 4 | 73.3 | FALSE | 0 | 0 |
| 2025-10-17 | 40 | 0 | CALL | 0 | 0 | 83.22 | FALSE | 0 | 0 |
| 2025-10-17 | 42.5 | 0 | CALL | 0 | 0 | 91.96 | FALSE | 0 | 0 |
| 2025-10-17 | 45 | 0 | CALL | 0 | 0 | 99.81 | FALSE | 0 | 0 |
| 2025-10-17 | 12.5 | 0 | PUT | 0 | 0 | 233.5 | FALSE | 0 | 0 |
| 2025-10-17 | 15 | 0 | PUT | 0 | 0 | 195.36 | FALSE | 0 | 0 |
| 2025-10-17 | 17.5 | 0 | PUT | 0 | 0 | 164.18 | FALSE | 0 | 0 |
| 2025-10-17 | 20 | 0 | PUT | 0 | 2 | 137.57 | FALSE | 0 | 0 |
| 2025-10-17 | 22.5 | 0 | PUT | 0 | 1 | 114.07 | FALSE | 0 | 0 |
| 2025-10-17 | 25 | 0 | PUT | 0 | 41 | 92.67 | FALSE | 0 | 0 |
| 2025-10-17 | 27.5 | 2.05 | PUT | 0 | 61 | 72.5 | FALSE | 0 | 0 |
| 2025-10-17 | 30 | 2.55 | PUT | 0 | 4 | 54.27 | FALSE | 0 | 0 |
| 2025-10-17 | 32.5 | 0 | PUT | 0 | 0 | 37.49 | TRUE | 0 | 0 |
| 2025-10-17 | 35 | 0 | PUT | 0 | 0 | 32.4 | TRUE | 0 | 0 |
| 2025-10-17 | 37.5 | 0 | PUT | 0 | 0 | 34.12 | TRUE | 0 | 0 |
| 2025-10-17 | 40 | 0 | PUT | 0 | 0 | 55.2 | TRUE | 0 | 0 |
| 2025-10-17 | 42.5 | 0 | PUT | 0 | 0 | 90.3 | TRUE | 0 | 0 |
| 2025-10-17 | 45 | 0 | PUT | 0 | 0 | 60.74 | TRUE | 0 | 0 |
| 2026-01-16 | 12.5 | 0 | CALL | 0 | 0 | 144.92 | TRUE | 0 | 0 |
| 2026-01-16 | 15 | 0 | CALL | 0 | 0 | 127.73 | TRUE | 0 | 0 |
| 2026-01-16 | 17.5 | 0 | CALL | 0 | 0 | 110.58 | TRUE | 0 | 0 |
| 2026-01-16 | 20 | 0 | CALL | 0 | 0 | 87.63 | TRUE | 0 | 0 |
| 2026-01-16 | 22.5 | 0 | CALL | 0 | 0 | 30.88 | TRUE | 0 | 0 |
| 2026-01-16 | 25 | 0 | CALL | 0 | 0 | 29.08 | TRUE | 0 | 0 |
| 2026-01-16 | 27.5 | 0 | CALL | 0 | 0 | 24.05 | TRUE | 0 | 0 |
| 2026-01-16 | 30 | 3.5 | CALL | 1 | 10 | 29.64 | TRUE | 3.5 | 0 |
| 2026-01-16 | 32.5 | 0 | CALL | 0 | 0 | 28.57 | FALSE | 0 | 0 |
| 2026-01-16 | 35 | 1.95 | CALL | 0 | 1 | 50.58 | FALSE | 0 | 0 |
| 2026-01-16 | 37.5 | 0.75 | CALL | 0 | 1 | 51.68 | FALSE | 0 | 0 |
| 2026-01-16 | 40 | 0 | CALL | 0 | 0 | 57.58 | FALSE | 0 | 0 |
| 2026-01-16 | 42.5 | 0 | CALL | 0 | 0 | 63.8 | FALSE | 0 | 0 |
| 2026-01-16 | 45 | 0 | CALL | 0 | 0 | 69.38 | FALSE | 0 | 0 |
| 2026-01-16 | 12.5 | 0 | PUT | 0 | 0 | 166.06 | FALSE | 0 | 0 |
| 2026-01-16 | 15 | 0 | PUT | 0 | 0 | 139.1 | FALSE | 0 | 0 |
| 2026-01-16 | 17.5 | 0 | PUT | 0 | 0 | 117.08 | FALSE | 0 | 0 |
| 2026-01-16 | 20 | 0 | PUT | 0 | 0 | 98.31 | FALSE | 0 | 0 |
| 2026-01-16 | 22.5 | 0 | PUT | 0 | 0 | 59.41 | FALSE | 0 | 0 |
| 2026-01-16 | 25 | 0 | PUT | 0 | 0 | 59.05 | FALSE | 0 | 0 |
| 2026-01-16 | 27.5 | 0 | PUT | 0 | 0 | 52.5 | FALSE | 0 | 0 |
| 2026-01-16 | 30 | 0 | PUT | 0 | 0 | 38.54 | FALSE | 0 | 0 |
| 2026-01-16 | 32.5 | 0 | PUT | 0 | 0 | 25.56 | TRUE | 0 | 0 |
| 2026-01-16 | 35 | 0 | PUT | 0 | 0 | 40.58 | TRUE | 0 | 0 |
| 2026-01-16 | 37.5 | 0 | PUT | 0 | 0 | 33.07 | TRUE | 0 | 0 |
| 2026-01-16 | 40 | 0 | PUT | 0 | 0 | 35.12 | TRUE | 0 | 0 |
| 2026-01-16 | 42.5 | 0 | PUT | 0 | 0 | 44.54 | TRUE | 0 | 0 |
| 2026-01-16 | 45 | 0 | PUT | 0 | 0 | 63.27 | TRUE | 0 | 0 |
Latest GLPG Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:58 PM EST | 100 | $54.06 |
| Jun 13, 2022 7:58 PM EST | 10 | $53.98 |
| Jun 13, 2022 7:58 PM EST | 1 | $53.98 |
| Jun 13, 2022 7:59 PM EST | 1 | $53.985 |
| Jun 13, 2022 7:59 PM EST | 100 | $53.99 |
Galapagos NV (GLPG) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320004215/0001171843-20-004215-index.htm |
| 2020-01-27 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1421876/000090221920000071/0000902219-20-000071-index.htm |
| 2019-07-17 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1421876/000110465919040709/0001104659-19-040709-index.htm |
| 2019-07-23 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1421876/000110465919041473/0001104659-19-041473-index.htm |
| 2019-08-29 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1421876/000110465919047927/0001104659-19-047927-index.htm |
| 2019-11-01 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1421876/000110465919059005/0001104659-19-059005-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1421876/000110465920021860/0001104659-20-021860-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1421876/000114036120003311/0001140361-20-003311-index.htm |
| 2019-05-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319003728/0001171843-19-003728-index.htm |
| 2019-06-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319003920/0001171843-19-003920-index.htm |
| 2019-06-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319004030/0001171843-19-004030-index.htm |
| 2019-06-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319004093/0001171843-19-004093-index.htm |
| 2019-07-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319004317/0001171843-19-004317-index.htm |
| 2019-07-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319004585/0001171843-19-004585-index.htm |
| 2019-07-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319004659/0001171843-19-004659-index.htm |
| 2019-09-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319005832/0001171843-19-005832-index.htm |
| 2019-09-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319005833/0001171843-19-005833-index.htm |
| 2019-09-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319006023/0001171843-19-006023-index.htm |
| 2019-09-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319006051/0001171843-19-006051-index.htm |
| 2019-09-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319006114/0001171843-19-006114-index.htm |
| 2019-10-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319006401/0001171843-19-006401-index.htm |
| 2019-10-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319006466/0001171843-19-006466-index.htm |
| 2019-10-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319006850/0001171843-19-006850-index.htm |
| 2019-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319006892/0001171843-19-006892-index.htm |
| 2019-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319007092/0001171843-19-007092-index.htm |
| 2019-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319007260/0001171843-19-007260-index.htm |
| 2019-11-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319007410/0001171843-19-007410-index.htm |
| 2019-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319007516/0001171843-19-007516-index.htm |
| 2019-11-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319007642/0001171843-19-007642-index.htm |
| 2019-11-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319007826/0001171843-19-007826-index.htm |
| 2019-12-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319008012/0001171843-19-008012-index.htm |
| 2019-12-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184319008255/0001171843-19-008255-index.htm |
| 2020-01-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320000139/0001171843-20-000139-index.htm |
| 2020-01-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320000140/0001171843-20-000140-index.htm |
| 2020-01-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320000174/0001171843-20-000174-index.htm |
| 2020-01-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320000237/0001171843-20-000237-index.htm |
| 2020-01-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320000469/0001171843-20-000469-index.htm |
| 2020-01-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320000556/0001171843-20-000556-index.htm |
| 2020-03-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320001794/0001171843-20-001794-index.htm |
| 2020-04-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320002640/0001171843-20-002640-index.htm |
| 2020-04-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320002674/0001171843-20-002674-index.htm |
| 2020-04-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320002689/0001171843-20-002689-index.htm |
| 2020-05-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320003977/0001171843-20-003977-index.htm |
| 2020-05-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320004053/0001171843-20-004053-index.htm |
| 2020-06-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320004164/0001171843-20-004164-index.htm |
| 2020-06-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320004215/0001171843-20-004215-index.htm |
| 2020-07-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320005194/0001171843-20-005194-index.htm |
| 2020-08-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320005906/0001171843-20-005906-index.htm |
| 2020-08-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320005998/0001171843-20-005998-index.htm |
| 2020-08-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320006087/0001171843-20-006087-index.htm |
| 2020-09-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320006405/0001171843-20-006405-index.htm |
| 2020-09-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320006525/0001171843-20-006525-index.htm |
| 2020-09-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320006651/0001171843-20-006651-index.htm |
| 2020-09-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320006681/0001171843-20-006681-index.htm |
| 2020-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320006727/0001171843-20-006727-index.htm |
| 2020-10-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320007002/0001171843-20-007002-index.htm |
| 2020-10-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320007061/0001171843-20-007061-index.htm |
| 2020-10-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320007261/0001171843-20-007261-index.htm |
| 2020-11-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320007481/0001171843-20-007481-index.htm |
| 2020-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000117184320007726/0001171843-20-007726-index.htm |
| 2019-08-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000119312519234109/0001193125-19-234109-index.htm |
| 2019-09-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000119312519250691/0001193125-19-250691-index.htm |
| 2019-10-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000119312519272244/0001193125-19-272244-index.htm |
| 2019-10-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000119312519274853/0001193125-19-274853-index.htm |
| 2020-03-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000119312520088879/0001193125-20-088879-index.htm |
| 2020-04-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000119312520126328/0001193125-20-126328-index.htm |
| 2020-05-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000119312520139028/0001193125-20-139028-index.htm |
| 2020-10-09 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1421876/000119312520267249/0001193125-20-267249-index.htm |
| 2019-07-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000155837019006344/0001558370-19-006344-index.htm |
| 2020-03-27 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1421876/000155837020003270/0001558370-20-003270-index.htm |
| 2020-08-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1421876/000155837020009632/0001558370-20-009632-index.htm |